Drugs in MeSH Category Purinergic P1 Receptor Antagonists

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Mpp Pharma	THEOPHYLLINE	theophylline	TABLET, EXTENDED RELEASE;ORAL	040560-003	Apr 21, 2006	AB	RX	No	No
Vintage Pharms	AMINOPHYLLINE	aminophylline	TABLET;ORAL	085409-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Hospira Inc	THEOPHYLLINE IN DEXTROSE 5% IN PLASTIC CONTAINER	theophylline	INJECTABLE;INJECTION	019211-004	Dec 14, 1984		DISCN	No	No
Heritage Pharma Avet	THEOPHYLLINE	theophylline	TABLET, EXTENDED RELEASE;ORAL	089763-001	Apr 30, 1990	AB	RX	No	No
Cosette Pharms Nc	TRUPHYLLINE	aminophylline	SUPPOSITORY;RECTAL	085498-002	Jan 3, 1983		DISCN	No	No
Fleming Pharms	AEROLATE SR	theophylline	CAPSULE, EXTENDED RELEASE;ORAL	085075-001	Nov 24, 1986		DISCN	No	No
Mpp Pharma	THEOPHYLLINE	theophylline	TABLET, EXTENDED RELEASE;ORAL	040560-002	Apr 21, 2006	AB	RX	No	Yes

Market Dynamics and Patent Landscape for Purinergic P1 Receptor Antagonists (NLM MeSH Class)

Last updated: May 30, 2026

Executive summary Purinergic P1 receptor antagonists sit at the intersection of adenosine-pathway modulation and oncology, inflammation, and CNS indications. The patent landscape is dominated by (1) chemical matter around adenosine receptor antagonists, (2) formulation and route-of-administration IP (oral solids, parenterals, long-acting injectables, transdermal where applicable), and (3) method-of-use claims that tie blockade of A1/A2A/A2B/A3 to specific diseases and biomarkers. Market dynamics are shaped by the adenosine axis’s centrality in immuno-oncology, but commercial uptake is constrained by efficacy durability, safety tradeoffs (cardiovascular and immunologic), and differentiation risk versus progressing adenosine pathway competitors (A2A agonists/antagonists, CD73, CD39, and downstream immunomodulators).

Because “Purinergic P1 Receptor Antagonists” is a MeSH class, the relevant patent scope spans multiple active ingredients and sub-classes. Without a drug-by-drug anchor (active ingredient or FDA product), it is not possible to produce a complete, accurate patent estate map, Orange Book status table, or litigation/Paragraph IV timeline for this entire MeSH class in a single response.